Liquidia Corporation (LQDA)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow LQDA in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on LQDA and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
LQDA at a glance
Key statistics
$3.25B
Market capitalization
- Previous close
- $36.35
- Open
- $36.62
- Day range
- $36.62 – $38.80
- Volume
- 2.04M
- Average volume (30 sessions)
- 5.10M
- Shares outstanding
- 37.75M
- Price / earnings
- 23.5
- Earnings per share
- $1.55
- Price / book
- 16.7
- Price / sales
- 7.2
- Beta (1 year, vs SPY)
- 0.64
Where the price sits in its year
52-week range
23% of the range
- Below the 52-week high
- -58.7%
- Above the 52-week low
- +76.4%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $40.09-9.3%
- 50-day average
- $58.30-37.7%
- 200-day average
- $53.95-32.6%
Between the conventional 30 and 70 bands.
+35.6%
1 week
-45.3%
1 month
-58.2%
3 months
+5.4%
Year to date
+61.7%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with LQDA
LQDA on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on LQDA.
See the plans →
Every planScreen names like LQDA
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on LQDA
Put LQDA on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on LQDA
See whether there is an open premium alert on LQDA, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
LQDA headlines
- Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting
Benzinga · Sep 29, 2025
- U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
GlobeNewswire Inc. · May 23, 2025
- Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
GlobeNewswire Inc. · May 12, 2025
- District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
GlobeNewswire Inc. · May 2, 2025
- Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
GlobeNewswire Inc. · Mar 12, 2025
- Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
GlobeNewswire Inc. · Oct 2, 2024
- Liquidia corp chief medical officer sells $18.4k in stock - Investing.com
Investing.com · Jul 15, 2024
- Liquidia Corp executive sells shares worth over $19,000 - Investing.com
Investing.com · Jul 15, 2024
SEC Form 4, most recent first
Insider filings
Kaseta Michael
−7.0K
CFO and COO · Option exercise
· Oct 9, 2026
JEFFS ROGER
+13.8K
Chief Executive Officer, Director · Option exercise
· Oct 9, 2026
Krepp Sarah
+3.2K
Chief Human Resource Officer · Option exercise
· Oct 9, 2026
Saggar Rajeev
+4.5K
Chief Medical Officer · Option exercise
· Oct 9, 2026
Adair Jason
+3.9K
Chief Business Officer · Option exercise
· Oct 9, 2026
Boyle Dana
−5.9K
Chief Accounting Officer · Open-market sale
$167.80K · Oct 12, 2026
Adair Jason
−7.3K
Chief Business Officer · Open-market sale
$207.93K · Oct 12, 2026
Kaseta Michael
−18.9K
CFO and COO · Open-market sale
$539.35K · Oct 12, 2026
About Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Morrisville, NC
- Employees
- 216
- Listed since
- Jul 26, 2018
- Website
- liquidia.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.